Abbott Laboratories (ABT)

Frankfurt


	Symbol		Exchange		Currency
	ABT		NYSE		USD	Real-time
	0Q15		London		USD	Real-time
	ABT		BIVA		MXN	Delayed
	ABT		Mexico		MXN	Delayed
	ABT		Switzerland		CHF	Delayed
	ABT		Xetra		EUR	Delayed
	ABT		Frankfurt		EUR	Delayed
	ABT		TradeGate		EUR	Delayed
	ABTCL		Santiago		CLP	Delayed
	ABTm		Buenos Aires		ARS	Delayed
	ABTT34		B3		BRL	Delayed
	ABT		Vienna		EUR	Real-time
	ABT_KZ		KASE		USD	Delayed
	ABT		Lima		USD	Delayed

Currency in EUR

Disclaimer

104.84

+0.24(+0.23%)

Closed09/10

Fair Value

Day's Range

104.68

105.00

52 wk Range

85.41

111.18

ABT Income Statement

Featured here, the Income Statement (earnings report) for Abbott Laboratories, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

31,904

34,608

43,075

43,653

40,109

Total Revenues Growth

+4.34%

+8.48%

+24.47%

+1.34%

-8.12%

Cost Of Revenues

13,231

15,003

18,080

19,083

17,919

Gross Profit

18,673

19,605

24,995

24,570

22,190

Gross Profit Growth

+4.42%

+4.99%

+27.49%

-1.7%

-9.69%

Gross Profit Margin %

58.53%

56.65%

58.03%

56.28%

55.32%

Other Operating Expenses, Total

13,916

14,143

15,791

15,457

14,970

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-0.91%	+1.63%	+11.65%	-2.12%	-3.15%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	2,440	2,420	2,738	2,741	2,619
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	9,540	9,591	11,006	10,703	10,385
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

4,757

5,462

9,204

9,113

7,220

Operating Income Growth

+23.94%

+14.82%

+68.51%

-0.99%

-20.77%

EBIT Margin %

14.91%

15.78%

21.37%

20.88%

18%

Net Interest Expenses

-576

-500

-490

-375

-252

Net Interest Expenses Growth

+20.11%

+13.19%

+2%

+23.47%

+32.8%

Interest Expense, Total

-670

-546

-533

-558

-637

Interest And Investment Income

94

46

43

183

385

Other Non Operating Expenses, Total

-41

21

6

-42

-63

EBT, Excl. Unusual Items

4,140

4,983

8,720

8,696

6,905

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-63

100

-

-111

-58

EBT, Incl. Unusual Items

4,077

4,968

8,211

8,306

6,664

EBT, Incl. Unusual Items Growth

+41.91%

+21.85%

+65.28%

+1.16%

-19.77%

EBT, Incl. Unusual Items Margin

12.78%

14.36%

19.06%

19.03%

16.61%

Income Tax Expense

390

497

1,140

1,373

941

Net Income to Company

3,687

4,495

7,071

6,933

5,723

Minority Interest

-

-

-

-

-

Net Income

3,687

4,495

7,071

6,933

5,723

Net Income Growth

+55.7%

+21.91%

+57.31%

-1.95%

-17.45%

Net Income Margin %

11.56%

12.99%

16.42%

15.88%

14.27%

Preferred Dividend and Other Adjustments

21

22

29

28

22

Net Income to Common Excl. Extra Items

3,666

4,449

7,042

6,905

5,701

Basic EPS - Continuing Operations

2.07

2.51

3.97

3.94

3.28

Basic EPS - Continuing Operations Growth

+57.19%

+21.02%

+58.1%

-0.71%

-16.82%

Diluted EPS - Continuing Operations

2.06

2.49

3.94

3.91

3.26

Diluted EPS - Continuing Operations Growth

+57.25%

+20.87%

+58.23%

-0.76%

-16.62%

Basic Weighted Average Shares Outstanding

1,768

1,773

1,775

1,753

1,740

Diluted Weighted Average Shares Outstanding

1,781

1,786

1,789

1,764

1,749

Dividend Per Share

1.32

1.53

1.82

1.92

2.08

Dividend Per Share Growth

+13.79%

+15.91%

+18.95%

+5.49%

+8.33%

EBITDA

7,771

8,789

12,742

12,380

10,463

EBITDA Growth

+9.2%

+13.1%

+44.98%

-2.84%

-15.48%

EBITDA Margin %